Uncategorized
New FDA Leadership Could Raise The Bar For Drug Approvals
A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply. read more
Lyft Is Executing Well But Analysts Caution About Uber And Waymo Competition
Lyft stock rises on $1.45B revenue, $750M buyback plan. Needham reiterates hold, Goldman Sachs upgrades to buy with PT of $20. Strong growth despite competition. Latest Ratings for LYFT Date Firm Action From To Mar 2022 Loop Capital Maintains Buy Mar 2022 Deutsche Bank Initiates Coverage On Hold Feb 2022 Morgan Stanley Maintains Equal-Weight View…
Cloudflare Nets $160 Target After $130M Deal Spikes Shares
Latest Ratings for NET Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Mizuho Maintains Neutral Feb 2022 Keybanc Maintains Overweight View More Analyst Ratings for NET View the Latest Analyst Ratings read more
Why Is Embecta Stock Falling On Friday?
Embecta reaffirms earnings outlook, trims revenue forecast, and boosts cash flow as restructuring and cost controls offset tariff and FX headwinds. read more
Coinbase Analysts Look Ahead To Q2 After Disappointing Q1: ‘Higher Crypto Prices… Increased Volumes’
Coinbase Global (NASDAQ:COIN) analysts highlight the company’s recent acquisition and how the future could be brighter with cryptocurrency prices jumping in the current second quarter after the company missed Latest Ratings for COIN Date Firm Action From To Mar 2022 Goldman Sachs Maintains Buy Feb 2022 Compass Point Maintains Neutral Feb 2022 Canaccord Genuity Maintains…